<DOC>
	<DOCNO>NCT01856413</DOCNO>
	<brief_summary>Patients receive liver transplantation hepatitis B virus ( HBV ) induce liver failure require longterm therapy prevent HBV reinfection transplant liver . The approved preventative treatment combination antihepatitis B immunoglobulin ( HBIg ) oral antiviral medication . In first 6 month liver transplantation , patient receive treatment intravenous HBIg maintain blood antihepatitis B ( antiHBs ) antibody concentration 100 IU/L , level consider safe prevent hepatitis B reinfection . Zutectra HBIg preparation subcutaneous injection approve EU 'prevention HBV reinfection HBV DNA negative patient ≥ 6 month liver transplantation hepatitis B induce liver failure ' . The purpose study show earlier subcutaneous HBIg treatment Zutectra liver transplantation prevent hepatitis B reinfection . Treatment subcutaneous HBIg ( Zutectra ) home manageable majority patient convenient patient compare intravenous treatment must take place hospital setting . Fourty patient take part study approximately 19 centre UK , France , Italy Spain . Patients eligible study receive treatment Zutectra 24 week . During study , safety effectiveness Zutectra assess check symptom hepatitis B related infection , well monitor blood level antiHBs antibody hepatitis B surface antigen ( HBsAg ) .</brief_summary>
	<brief_title>A Clinical Trial Zutectra Patients Who Recently Received Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Written inform consent obtain prior orthotopic liver transplantation ( OLT ) 3 month OLT Historical evidence within last 4 week HBVDNA undetectable time point signature Informed Consent Male female patient ( age 1875 year ) Patients diagnosis liver failure hepatitis B infection Patients undergoing liver transplantation retransplantation HBsAg negative day 7 day 14 OLT HBVDNA undetectable OLT Serum HBs antibody concentration day 7 day 14 OLT ≥ 400 IU/l Stable patient condition opinion investigator would permit safe participation study Willingness fill patient diary Retransplantation due viral recurrence Positive HIV HCV test time transplantation HBVDNA positive OLT Patients receive organ HBsAg positive donor Pregnancy unreliable contraceptive measure lactation period ( female ) Known intolerance immunoglobulin comparable substance ( e.g . vaccination reaction ) Known intolerance protein human origin Participation another interventional clinical trial within 90 day enter study study and/or previous participation study ( except screen failure ) Suspicion drug and/or alcohol abuse Inability lack motivation participate study Employee direct relative employee CRO , study site , Biotest</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Hepatitis B virus re-infection</keyword>
	<keyword>HBV-DNA negative</keyword>
	<keyword>Liver transplantation</keyword>
</DOC>